StageZero Life Sciences Ltd (TO:SZLS) — Market Cap & Net Worth
Market Cap & Net Worth: StageZero Life Sciences Ltd (SZLS)
StageZero Life Sciences Ltd (TO:SZLS) has a market capitalization of $3.58 Million (CA$4.94 Million) as of May 2, 2026. Listed on the TO stock exchange, this Canada-based company holds position #28949 globally and #1376 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying StageZero Life Sciences Ltd's stock price CA$0.04 by its total outstanding shares 123553000 (123.55 Million). Analyse StageZero Life Sciences Ltd (SZLS) cash flow conversion to see how efficiently the company converts income to cash.
StageZero Life Sciences Ltd Market Cap History: 2015 to 2025
StageZero Life Sciences Ltd's market capitalization history from 2015 to 2025. Data shows change from $21.45 Million to $3.58 Million (-32.83% CAGR).
StageZero Life Sciences Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how StageZero Life Sciences Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.55x
StageZero Life Sciences Ltd's market cap is 1.55 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $21.45 Million | $325.81K | -$6.02 Million | 65.84x | N/A |
| 2016 | $221.65 Million | $1.05 Million | -$5.91 Million | 210.27x | N/A |
| 2017 | $164.45 Million | $411.67K | -$2.95 Million | 399.48x | N/A |
| 2018 | $35.75 Million | $185.87K | -$3.94 Million | 192.34x | N/A |
| 2019 | $35.75 Million | $138.70K | -$4.31 Million | 257.75x | N/A |
| 2020 | $67.03 Million | $4.15 Million | -$7.18 Million | 16.15x | N/A |
| 2021 | $26.81 Million | $5.07 Million | -$7.68 Million | 5.29x | N/A |
| 2022 | $5.36 Million | $3.80 Million | -$11.42 Million | 1.41x | N/A |
| 2023 | $4.47 Million | $2.88 Million | -$12.53 Million | 1.55x | N/A |
Competitor Companies of SZLS by Market Capitalization
Companies near StageZero Life Sciences Ltd in the global market cap rankings as of May 2, 2026.
Key companies related to StageZero Life Sciences Ltd by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #126 globally with a market cap of $176.29 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #189 globally with a market cap of $123.72 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #578 globally with a market cap of $45.31 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #643 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #126 | Thermo Fisher Scientific Inc | NYSE:TMO | $176.29 Billion | $469.21 |
| #189 | Danaher Corporation | NYSE:DHR | $123.72 Billion | $175.15 |
| #578 | IDEXX Laboratories Inc | NASDAQ:IDXX | $45.31 Billion | $567.46 |
| #643 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
StageZero Life Sciences Ltd Historical Marketcap From 2015 to 2025
Between 2015 and today, StageZero Life Sciences Ltd's market cap moved from $21.45 Million to $ 3.58 Million, with a yearly change of -32.83%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | CA$3.58 Million | 0.00% |
| 2024 | CA$3.58 Million | -20.00% |
| 2023 | CA$4.47 Million | -16.67% |
| 2022 | CA$5.36 Million | -80.00% |
| 2021 | CA$26.81 Million | -60.00% |
| 2020 | CA$67.03 Million | +87.50% |
| 2019 | CA$35.75 Million | 0.00% |
| 2018 | CA$35.75 Million | -78.26% |
| 2017 | CA$164.45 Million | -25.81% |
| 2016 | CA$221.65 Million | +933.33% |
| 2015 | CA$21.45 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of StageZero Life Sciences Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.58 Million USD |
| MoneyControl | $3.58 Million USD |
| MarketWatch | $3.58 Million USD |
| marketcap.company | $3.58 Million USD |
| Reuters | $3.58 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About StageZero Life Sciences Ltd
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers fr… Read more